KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $9.4 million.

  • Acadia Pharmaceuticals' Cash from Financing Activities rose 341604.48% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 18308.44%. This contributed to the annual value of $6.8 million for FY2024, which is 7276.06% down from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $9.4 million for Q3 2025, which was up 341604.48% from $16.0 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Cash from Financing Activities high stood at $16.0 million for Q2 2025, and its period low was $268000.0 during Q3 2024.
  • In the last 5 years, Acadia Pharmaceuticals' Cash from Financing Activities had a median value of $3.6 million in 2024 and averaged $4.5 million.
  • In the last 5 years, Acadia Pharmaceuticals' Cash from Financing Activities soared by 434285.71% in 2023 and then plummeted by 9789.82% in 2024.
  • Acadia Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $4.4 million in 2021, then plummeted by 63.02% to $1.6 million in 2022, then surged by 236.68% to $5.4 million in 2023, then plummeted by 63.77% to $2.0 million in 2024, then skyrocketed by 378.57% to $9.4 million in 2025.
  • Its Cash from Financing Activities stands at $9.4 million for Q3 2025, versus $16.0 million for Q2 2025 and $1.8 million for Q1 2025.